BPC-157: What the Research Shows

BPC-157, short for Body Protection Compound-157, is a synthetic peptide consisting of 15 amino acids (a pentadecapeptide) derived from a protective protein found naturally in human gastric juice. It was first isolated and characterized by researchers at the University of Zagreb in Croatia, where the majority of BPC-157 research has been conducted over the past three decades.

The peptide's sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) is a partial sequence of a larger protein called BPC, which is secreted in the stomach and appears to play a role in maintaining the integrity of the gastrointestinal lining. Unlike many peptides, BPC-157 is notably stable in human gastric juice — it is not degraded by stomach acid, which is unusual and has led researchers to investigate oral administration as a viable route (Sikiric et al., 2024; PMID: 38675421).

BPC-157 has attracted enormous public attention since 2024, driven by mentions from high-profile figures in the health and biohacking space and amplified by the FDA's controversial decision to ban it from compounding. It is sometimes referred to as the "Wolverine peptide" in popular media due to its purported healing properties, though this characterization significantly overstates the evidence.

The mechanisms through which BPC-157 exerts its effects have been studied primarily in animal and in-vitro models. Research suggests several interconnected pathways:

Angiogenesis via VEGFR2 signaling. The most well-characterized mechanism involves activation of vascular endothelial growth factor receptor 2 (VEGFR2). When BPC-157 activates VEGFR2, it triggers the PI3K-Akt-eNOS pathway, increasing production of nitric oxide (NO) in blood vessel walls. This promotes formation of new blood vessels (angiogenesis), which is critical for tissue repair in poorly vascularized areas like tendons and ligaments (Hsieh et al., 2020; PMID: 33033295).

Dual nitric oxide pathways. In addition to the VEGF-dependent pathway, BPC-157 also activates a VEGF-independent route through Src-Caveolin-1-eNOS signaling. This dual-pathway activation appears to provide more robust and sustained nitric oxide production, supporting vasodilation and continuous blood flow to healing tissues (Hsieh et al., 2020; PMID: 33033295).

Growth hormone receptor upregulation. In tendon fibroblasts, BPC-157 has been shown to increase expression of growth hormone receptors, which may enhance the cells' responsiveness to growth signals during the repair process (Chang et al., 2014; PMID: 25405516).

Neurotransmitter system interactions. A 2024 review documented BPC-157's interactions with multiple neurotransmitter systems including dopamine, serotonin, GABA, and the nitric oxide system, suggesting it may function as a broad cytoprotective mediator rather than targeting a single pathway (Sikiric et al., 2024; PMID: 38675421).

It is important to note that these mechanisms have been characterized almost entirely in animal models and cell cultures. Whether the same pathways are activated at the same magnitude in humans remains unconfirmed.

The most extensively studied application of BPC-157 is musculoskeletal healing, particularly tendon repair.

A 2025 systematic review examined 36 studies published from 1993 to 2024 and found that 35 were preclinical (animal) studies while only one was a clinical study involving humans. The review concluded that BPC-157 promotes healing by boosting growth factors and reducing inflammation, with improved outcomes in muscle, tendon, ligament, and bone injury models (Vasireddi et al., 2025; PMID: 40756949).

In a frequently cited 2003 rat study, Staresinic and colleagues demonstrated that BPC-157 administered intraperitoneally at doses of 10 micrograms, 10 nanograms, or 10 picograms accelerated healing of transected Achilles tendons. The treated animals showed improved biomechanical properties (increased load of failure and Young's modulus), higher functional scores, and superior collagen and fibroblast formation compared to controls (Staresinic et al., 2003; PMID: 14554208).

A 2011 study by Chang et al. further characterized the tendon healing mechanism, finding that BPC-157 accelerated tendon explant outgrowth and promoted cell survival and migration, though it did not directly stimulate cell proliferation (Chang et al., 2011; PMID: 21030672).

Human evidence for musculoskeletal applications is extremely limited. One small study reported that 7 of 12 participants with chronic knee pain experienced relief lasting more than six months after a single intra-articular BPC-157 injection. However, this study's small sample size, lack of placebo control, and single-site design make it insufficient to draw clinical conclusions.

The gap between the robust animal evidence and the near-absence of human data is the central challenge in evaluating BPC-157 for musculoskeletal applications.

BPC-157 was originally investigated for its gastroprotective properties, and gastrointestinal healing remains one of its most studied applications in animal models.

Research has shown that BPC-157 reduces ulcer area and accelerates healing in multiple gastric ulcer models in rats, with both intramuscular and intragastric (oral) administration showing efficacy. Intramuscular administration appeared slightly more effective than oral administration in some models (Xue et al., 2004; PMID: 15052688).

A comprehensive review noted that BPC-157 was the only agent consistently effective in all models of acute and chronic injury across the entire gastrointestinal tract — esophagus, stomach, duodenum, and lower GI tract — when administered intraperitoneally, orally, or locally (Seiwerth et al., 2021; PMID: 34248628).

Animal studies have also explored BPC-157 in models of inflammatory bowel conditions, intestinal anastomosis healing, and esophageal damage, with generally positive results across these contexts.

No human clinical trials have evaluated BPC-157 for gastrointestinal conditions. The animal data is consistent and extensive, but the translation to human GI healing has not been tested in controlled clinical settings.

Beyond tendons and the GI tract, BPC-157 has been studied for wound healing across various tissue types in animal models.

A 2021 review in Frontiers in Pharmacology summarized decades of wound healing research, finding that BPC-157 consistently accelerated healing in skin wounds, muscle injuries, ligament tears, and bone fractures in animal models. The effects were attributed to VEGFR2-mediated angiogenesis and nitric oxide system modulation (Seiwerth et al., 2021; PMID: 34248628).

In these studies, BPC-157 appears to work by increasing blood supply to injured areas through new vessel formation, which is particularly relevant for tissues that naturally have poor blood supply (such as tendons and certain ligaments).

Human data for wound healing applications does not exist. All evidence comes from animal models and cell culture studies.

Human safety data is extremely limited. As of 2026, only three small human studies have been published:

In the most recent, Lee and Burgess (2025) conducted an IRB-approved pilot study administering intravenous BPC-157 to two healthy adults (10mg on day 1, 20mg on day 2). No adverse events were observed, and no clinically meaningful changes occurred in vital signs, ECG, liver, kidney, thyroid, or glucose biomarkers. Plasma levels returned to baseline within 24 hours (Lee & Burgess, 2025; PMID: 40131143). However, a study of 2 participants provides essentially no statistical power to detect safety signals.

In animal studies, gross necropsy analysis revealed no adverse changes in liver, spleen, thymus, and gastric wall following single and repeat doses, with no microscopic histopathologic changes across major organs. However, most animal studies were under 4 weeks in duration, and long-term effects remain uncharacterized.

The primary theoretical safety concern is cancer risk through angiogenesis. BPC-157 is a potent stimulator of new blood vessel formation via VEGFR2 upregulation — the same pathway that is active in approximately 50% of human cancers. While no study has demonstrated that BPC-157 causes cancer, the concern is mechanistically plausible: enhanced angiogenesis could theoretically supply blood to existing tumors or precancerous growths.

Some researchers note that BPC-157's VEGF modulation appears to be context-sensitive, upregulating in response to tissue injury signals rather than constitutively, which may limit activity in non-injured tissue including tumor environments. However, this has not been tested in cancer models with adequate rigor.

BPC-157 is generally not recommended for individuals with active malignancies, a recent history of cancer, or a strong family history of cancer.

Other considerations include the complete absence of standardized manufacturing for research-grade BPC-157. Peptide purity varies significantly between sources, and contamination with other substances or degradation products is a real concern that introduces unknown safety variables.

FDA Status: Banned from Compounding (Category 2)

In late 2023, the FDA placed BPC-157 on the Category 2 list of bulk drug substances, classifying it as a "Substance with Safety Concerns." This means compounding pharmacies are prohibited from using BPC-157 bulk powder to make medications for human use under Section 503A of the Federal Food, Drug, and Cosmetic Act.

The FDA's stated reasons for the ban include potential immune reactions (immunogenicity), manufacturing impurities in bulk peptide production, and the lack of adequate human safety data. The agency has noted that selling BPC-157 for human use constitutes distributing an adulterated and misbranded unapproved drug.

There is no legal basis for selling BPC-157 as a drug, food, or dietary supplement in the United States. The FDA has indicated it may take enforcement action against compounding pharmacies that continue to produce it.

Several legal challenges to the Category 2 classification are ongoing. Physician groups, compounding pharmacies, and patient advocacy organizations have argued that the FDA's process was insufficient and that compounded BPC-157 served legitimate medical needs that cannot be met by approved therapies.

WADA Status: Prohibited

Since 2022, BPC-157 has been explicitly listed as an example substance under Section S0 (Non-Approved Substances) of the World Anti-Doping Agency Prohibited List. It is banned at all times — both in and out of competition. There is no basis for granting a Therapeutic Use Exemption (TUE) because BPC-157 is not an approved therapeutic agent in any country. Athletes under WADA jurisdiction (including Olympics, NCAA, and most professional leagues) face sanctions if BPC-157 is detected.

The following dosages have been reported in published studies. This information is provided for reference purposes only and does not constitute a dosage recommendation.

Animal studies (rat models): In the Staresinic et al. (2003) Achilles tendon study, BPC-157 was administered intraperitoneally at 10 micrograms/kg, 10 nanograms/kg, or 10 picograms/kg body weight. Positive effects were observed at all three dose levels (PMID: 14554208).

In gastric ulcer models, Xue et al. (2004) administered BPC-157 at 10 micrograms/kg via both intramuscular and intragastric routes (PMID: 15052688).

Human studies: In the Lee and Burgess (2025) IV safety pilot, two participants received 10mg intravenously on day 1 and 20mg intravenously on day 2, infused over one hour in 250cc normal saline (PMID: 40131143).

In the knee pain study, a single intra-articular injection was administered, though the exact dose varies by report.

There are no established, evidence-based dosage guidelines for BPC-157 in humans. The dosages used in the limited human studies may not represent optimal, safe, or effective doses.